Inhibition of central monoamine oxidase by imidazoline2 site-selective ligands.
Lalies
M D
MD
Psychopharmacology Unit, University of Bristol, School of Medical Sciences, UK.
Hibell
A
A
Hudson
A L
AL
Nutt
D J
DJ
D000818:Animals; D001549:Benzamides / Q000494:pharmacology; D001665:Binding Sites; D001921:Brain / Q000201:enzymology; D003010:Clorgyline / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology*; D054755:Imidazoline Receptors; D007527:Isoenzymes / Q000378:metabolism; D007700:Kinetics; D008024:Ligands; D020912:Moclobemide; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D010627:Phenethylamines / Q000378:metabolism; D051381:Rats; D011955:Receptors, Drug / Q000819:agonists / Q000378:metabolism*; D012642:Selegiline / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism
D001549:Benzamides; D007093:Imidazoles; D054755:Imidazoline Receptors; D007527:Isoenzymes; D008024:Ligands; D008996:Monoamine Oxidase Inhibitors; D010627:Phenethylamines; D011955:Receptors, Drug; D012642:Selegiline; D012701:Serotonin; D008995:Monoamine Oxidase; D003010:Clorgyline; D020912:Moclobemide